J&J’s Risperdal Consta Approved In Japan
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare April 22 approved a long-acting antipsychotic for schizophrenia, Risperdal Consta (risperidone), marketed in Japan by Janssen Pharmaceutical K.K, and manufactured by Johnson & Johnson in collaboration with Alkermes in the U.S